OTC Naloxone In US Could Limit Access Due To Costs, Comments On Emergent Switch NDA Argue

 
• By Malcolm Spicer
  
The FDA joint advisory committee will meet on 15 February to discuss Emergent BioSolution's proposed OTC switch of NARCAN. • Source: Shutterstock

More from Approval Standards

More from Pathways & Standards